Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Steigbigel, Roy T., Cooper, David A., Teppler, Hedy, Eron, Joseph J., Gatell, Jose M., Kumar, Princy N., Rockstroh, Jurgen K., Schechter, Mauro, Katlama, Christine, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R., Lazzarin, Adriano, Lennox, Jeffrey L., Clotet, Bonaventura, Zhao, Jing, Wan, Hong, Rhodes, Rand R., Strohmaier, Kim M., Barnard, Richard J., Isaacs, Robin D., Nguyen, Bach-Yen T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076431/
https://ncbi.nlm.nih.gov/pubmed/20085491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/650002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados